Brokerages Expect LianBio (NASDAQ:LIAN) Will Announce Earnings of -$0.26 Per Share

Equities research analysts expect that LianBio (NASDAQ:LIANGet Rating) will post earnings of ($0.26) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for LianBio’s earnings. The highest EPS estimate is ($0.22) and the lowest is ($0.31). The firm is scheduled to report its next earnings results on Monday, January 1st.

On average, analysts expect that LianBio will report full-year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.65) to ($1.07). For the next year, analysts expect that the company will report earnings of ($1.73) per share, with EPS estimates ranging from ($2.20) to ($1.44). Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow LianBio.

LianBio (NASDAQ:LIANGet Rating) last posted its quarterly earnings data on Wednesday, March 30th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.44.

Separately, Zacks Investment Research lowered LianBio from a “hold” rating to a “sell” rating in a report on Tuesday, April 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Based on data from, LianBio presently has a consensus rating of “Hold” and an average price target of $23.19.

A number of large investors have recently modified their holdings of LIAN. Perceptive Advisors LLC purchased a new stake in shares of LianBio during the 4th quarter valued at approximately $346,931,000. Tybourne Capital Management HK Ltd. bought a new position in LianBio in the 4th quarter worth about $20,415,000. Alliancebernstein L.P. purchased a new position in LianBio during the 4th quarter valued at about $19,741,000. Vida Ventures Advisors LLC purchased a new stake in shares of LianBio in the fourth quarter worth about $14,058,000. Finally, Deerfield Management Company L.P. Series C bought a new position in shares of LianBio in the fourth quarter valued at approximately $10,982,000. Hedge funds and other institutional investors own 83.37% of the company’s stock.

LIAN stock opened at $2.15 on Thursday. The firm has a 50 day simple moving average of $3.95. LianBio has a 12-month low of $2.15 and a 12-month high of $16.37.

LianBio Company Profile (Get Rating)

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.

See Also

Get a free copy of the Zacks research report on LianBio (LIAN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for LianBio (NASDAQ:LIAN)

Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with's FREE daily email newsletter.